Introduction Indian Pharmaceutical market, SWOT analysis, PEST Analysis, Timeline analysis of Sun Pharma, Glaxo Smith Kline, Mankind, CIPLA and Zydus Cadila.
The Indian markets and financial institutions stand out as sound, stable and better
regulated in contrast to developed economies. As a result, India can continue to be an
attractive market in view of its strong and stable fundamentals and the resilience which
Indian economy has displayed so far
This ppt gives an overview of the Indian Pharmaceutical sector. We have concentrated on 5 aspects of the sector and analysed it. The covered heads are history, business model, Marketing, Competitor analysis, Financials and Trends.
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
The Indian markets and financial institutions stand out as sound, stable and better
regulated in contrast to developed economies. As a result, India can continue to be an
attractive market in view of its strong and stable fundamentals and the resilience which
Indian economy has displayed so far
This ppt gives an overview of the Indian Pharmaceutical sector. We have concentrated on 5 aspects of the sector and analysed it. The covered heads are history, business model, Marketing, Competitor analysis, Financials and Trends.
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
indian Pharmaceutical industry export import overviewbipindapin
Pharmaceutical Industry-EXPORT IMPORT INDIA
The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals licensed for use as medications. Pharmaceutical companies are allowed to deal in generic and/or brand medications and medical devices
India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors without Borders, the UNCTAD etc.
PRESENT SCENARIO OF INDIAN PHARMACEUTICAL INDUSTRY IN VIEW OF GLOBAL ...sridivyaannavarapu
THE INDIAN GOVERNMENT HAS STARTED TO ENCOURAGE THE GROWTH OF DRUG MANUFACTURING BY INDIAN COMPANIES IN THE EARLY 1960s. AT PRESENT THERE ARE MANY NUMBER OF PHARMACEUTICAL COMPANIES IN INDIA WITH MANY NOVEL DRUG INVENTORIES
Pharmaceutical market india a comprehensive industry analysis - Reports CornerReports Corner
"1.0 Summary
“Pharmaceutical Market: India, A Competitive Industry Analysis” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.
The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $13 billion. It is forecast to reach $50 billion by 2015 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $74 billion.
This report describes the current therapeutics that are propelling the biopharmaceutical market in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
https://www.reportscorner.com/reports/15826/Pharmaceutical-Market:-India-A-Comprehensive-Industry-Analysis/
Indian pharmaceutical industry: Policies, achievements and challengesRajesh Kochhar
Indian pharmaceutical industry is a success story from a national as well as third-world perspective. India accounts for 10% of world production and ranks third in the world in terms of volume. In value terms the share is only 1.4% and the rank 14th.
his statistic underlines the important fact that India produces world-class generic drugs at a very low cost. Indian domestic pharma market, currently evaluated at $12 bn, is largely self-sufficient with patented drugs playing a minimal role.
Advantages of Pharma in India, Market Share and Economic Drivers, Structure of Pharma Sector, Evolution of Pharma, Revenue %, Market Share, Porter 5 Force Model, BCG Matrix, Government Policies, Opportunities.
I have to try to share some knowledge about the Indian health care sector. I have put some data to get more and more knowledge which can easily understand.
Cadila Healthcare: Sales jump 22% during Q4FY14, buy - Firstcall India EquityIndiaNotes.com
Cadila Healthcare has posted 22% jump in its sales from Rs16119.00 mn to Rs19685.00 mn in current March quarter. At CMP of Rs886.20 the stock P/E ratio is at 17.81 x FY15E and 15.95 x FY16E respectively. Maintain buy
indian Pharmaceutical industry export import overviewbipindapin
Pharmaceutical Industry-EXPORT IMPORT INDIA
The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals licensed for use as medications. Pharmaceutical companies are allowed to deal in generic and/or brand medications and medical devices
India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors without Borders, the UNCTAD etc.
PRESENT SCENARIO OF INDIAN PHARMACEUTICAL INDUSTRY IN VIEW OF GLOBAL ...sridivyaannavarapu
THE INDIAN GOVERNMENT HAS STARTED TO ENCOURAGE THE GROWTH OF DRUG MANUFACTURING BY INDIAN COMPANIES IN THE EARLY 1960s. AT PRESENT THERE ARE MANY NUMBER OF PHARMACEUTICAL COMPANIES IN INDIA WITH MANY NOVEL DRUG INVENTORIES
Pharmaceutical market india a comprehensive industry analysis - Reports CornerReports Corner
"1.0 Summary
“Pharmaceutical Market: India, A Competitive Industry Analysis” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.
The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $13 billion. It is forecast to reach $50 billion by 2015 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $74 billion.
This report describes the current therapeutics that are propelling the biopharmaceutical market in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
https://www.reportscorner.com/reports/15826/Pharmaceutical-Market:-India-A-Comprehensive-Industry-Analysis/
Indian pharmaceutical industry: Policies, achievements and challengesRajesh Kochhar
Indian pharmaceutical industry is a success story from a national as well as third-world perspective. India accounts for 10% of world production and ranks third in the world in terms of volume. In value terms the share is only 1.4% and the rank 14th.
his statistic underlines the important fact that India produces world-class generic drugs at a very low cost. Indian domestic pharma market, currently evaluated at $12 bn, is largely self-sufficient with patented drugs playing a minimal role.
Advantages of Pharma in India, Market Share and Economic Drivers, Structure of Pharma Sector, Evolution of Pharma, Revenue %, Market Share, Porter 5 Force Model, BCG Matrix, Government Policies, Opportunities.
I have to try to share some knowledge about the Indian health care sector. I have put some data to get more and more knowledge which can easily understand.
Cadila Healthcare: Sales jump 22% during Q4FY14, buy - Firstcall India EquityIndiaNotes.com
Cadila Healthcare has posted 22% jump in its sales from Rs16119.00 mn to Rs19685.00 mn in current March quarter. At CMP of Rs886.20 the stock P/E ratio is at 17.81 x FY15E and 15.95 x FY16E respectively. Maintain buy
Presented by Amit Pradhan, CISO, Cipla, at CISO Platform Annual Summit, 2013. He heads the corporate information security group and IT security division for Cipla, one of the largest pharmaceutical company in India.
“SWOT ANALYSIS OF NEW PHARMACEUTICAL COMPANY”Dharmik Bhatt
Main Objective
To find the Strength, weakness, Opportunities and threat of the company and all new pharmaceutical companies.
To find out the perception and expectation of doctors and retailers towards the new pharmaceutical company.
Sub Objectives
To find out the big player of the market (Tough Competitor).
To find the way for new pharmaceutical company from tough competition.
To create strategy for company with the help of research detail.
To analyze Vadodara market for company.
To create good communication bridge between new company to doctors and retailers, that full feel all require expectation of both.
Current regulatory challenges in indian pharmaceutical industryVikas Rathee
India is the 3rd largest in terms of volume and 13th in terms of value all over the world as we still struggle in terms of quality so in this ppt i show some challenges faced by Indian Pharmaceutical Industry
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
Model Attribute Check Company Auto PropertyCeline George
In Odoo, the multi-company feature allows you to manage multiple companies within a single Odoo database instance. Each company can have its own configurations while still sharing common resources such as products, customers, and suppliers.
Macroeconomics- Movie Location
This will be used as part of your Personal Professional Portfolio once graded.
Objective:
Prepare a presentation or a paper using research, basic comparative analysis, data organization and application of economic information. You will make an informed assessment of an economic climate outside of the United States to accomplish an entertainment industry objective.
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
Palestine last event orientationfvgnh .pptxRaedMohamed3
An EFL lesson about the current events in Palestine. It is intended to be for intermediate students who wish to increase their listening skills through a short lesson in power point.
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
Francesca Gottschalk - How can education support child empowerment.pptxEduSkills OECD
Francesca Gottschalk from the OECD’s Centre for Educational Research and Innovation presents at the Ask an Expert Webinar: How can education support child empowerment?
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
9. Concentration of Pharma mfg units
in India (%)
30%
15%
7.5%7.5%
5.5%
34.5% Maharashtra 30%
Gujarat 15%
West Begal 7.5%
Andhra Pradesh 7.5%
Tamilnadu 5.5%
Others 34.5%
10. Beginning
India saw its first pharmaceutical company in 1930,
Bengal Chemicals and Pharmaceuticals works
Till 1970s Indian pharmaceutical market was non
existent
11. In Last 2 decades
5 Central Public Sector Units
20,000 registered units
250 large units
about 8000 Small Scale Units
12. India’s Pharma sector at a glance
$18.4 billion
Domestic Pharma
Market in FY14
$55.9 billion (23.9% +)
Estimated Pharma
Market Size in 2020
$16.6 billion
Pharma Exports in FY15
74% Share of Indian Companies
in the Pharma Market in 2015
60% Share of Urban Regions
in the Domestic Pharma
Market in 2013
5%Pharma FDI as a Share
of Total FDI in India in FY14
13. Current Scenario
India is now among the top five pharmaceutical
emerging markets.
Domestic Pharma market to grow at 10-12 per cent
in FY15 as compared to 9 per cent in FY14
Generic drugs account for 20 per cent of global
exports in terms of volume, making the country
the largest provider of generic medicines globally
14.
15. Strengths
Higher GDP growth leading to increased disposable
income in the hands of general public and their
positive attitude towards spending on healthcare.
highly skilled set of labor force and proven track
record in design of high technology manufacturing
devices.
Demographic potential
16. Cont…
Well established R&D facilities.
Low cost of labor, innovation, manufacturing and
operations.
Property rights supported by well-developed judicial
system.
17. Weaknesses
Stringent pricing regulations affecting the profitability
of pharma companies.
Poor all-round infrastructure is a major challenge.
Presence of more unorganized players versus the
organized ones, resulting in an increasingly
competitive environment, characterized by stiff price
competition.
Poor health insurance coverage.
18. Cont…
Inadequate emphasis on Biosciences in education
system leading to slower development in areas related
to Biology giving away advantage to China.
India has a low level of government spending on
healthcare, at 1% of the GDP
Competency in API/Formulation, intellectual property
creation, facility design and maintenance, global
regulatory and legal affairs, and managing international
work force is limited to a few players among the big
players
19. Opportunity
Opening of the health insurance sector and increase in
per capita income - the growth drivers for the
pharmaceutical industry
India, a potentially preferred global outsourcing hub for
pharmaceutical products due to low cost of skilled labour.
Health insurance is growing.
Global demand for generics rising
20. Cont…
The government is increasing spend on healthcare
Indian population is spending an increased amount of
money on healthcare, Changing disease profile and
favorable demographics
Increased penetration in the non - metro markets
Significant investment from MNCs
Public-Private Partnerships for strengthening
infrastructure
22. Cont…
India has a very high potential for developing as a center
for international clinical trials due to its rich diversity
There is a possibility of greater returns from an Indian
entry into mature markets like Brazil, Japan, Russia, etc
Rapid urbanization -Around 742 million people reside in
rural areas. There is a significant gap between the
number of people residing in villages that require
treatment, and quality treatment and medicines
reaching these villages
23. Threats
Other low-cost countries such as China , Thailand and
Israel affecting outsourcing demand for Indian
pharmaceutical products
Skilled Labour shortage
Wage inflation
Government expanding the umbrella of the Drugs Price
Control Order (DPCO)
24. Cont…
Competition from other emerging economies
Entry of foreign players (well-equipped technology-
based products) into the Indian market.
Product patent regime poses serious challenge to
domestic industry unless it invests in research and
development.
25. Cont…
Mergers and acquisitions by foreign companies
particularly multinational corporations of a few
Indian generic leaders may completely change the
direction of India’s pharmaceutical movement
neutralizing its thrust on generics and cost
competitiveness
26.
27. Political Factors
Political factors include government regulations
and legal issues and define both formal and
informal rules under which the firm must operate.
Some examples include:
Tax policy
Employment laws
Environmental regulations
Trade restrictions and tariffs
Political stability
28. National Pharmaceutical Pricing Policy (NPPP)
2012
The Indian government introduced NPPP in 2012 to regulate the
prices of 348 essential drugs, based on their strengths and dosages.
Manufacturers are allowed to sell these drugs on or below the price
fixed by the government.
The policy is applicable to imported drugs as well.
IMPLICATION
Implementation of NPPP resulted in decline of profit margins for
products under regulation from 20% to 16% and 10% to 8% for
retailers and stockiest respectively during 2012–13.
The policy has resulted in significant uncertainty among stockists
on whether to continue with the business amid low profit sand
margin reduction
29. Medical Council of India (MCI) Guidelines
on sales and marketing practices
MCI guidelines were issued to ensure transparency in
sales and prevent unethical practices of some doctors.
MCI aimed to stop medical professionals from
prescribing drugs in exchange of bribe from drug
manufacturers.
IMPLICATION
Tax authorities use the Central Board of Direct Taxes
(CBDT) circular based on MCI guidelines to decide on
permissible sales and marketing expenses.
30. Compulsory licensing
India has adopted compulsory licensing on the following
grounds under Section 84 of the Indian Patent Act:
The drug did not meet reasonable requirements of the citizens,
The drug was not reasonably priced
The patent was not locally manufactured.
IMPLICATION
The imposition of this regulation paved way for production of
low-cost generic medicines of the branded patent
drugs.Thus,costly,branded life saving drugs are available at a
cheaper rates to the Indian population.
The regulation affects the brand value of branded drugs
manufactured by MNCs, and thus has been opposed by them
31. Economic Factors
Economic factors affect the purchasing power of
potential customers and the firm's cost of capital.
The following are examples of factors in the macro
economy:
Labour Cost
Skilled Workers
Infrastructure quality
Inflation rate
32. Social Factors
Social factors include the demographic and
cultural aspects of the external macro
environment. These factors affect customer needs
and the size of potential markets. Some social
factors include:
Health consciousness
Population growth rate
Age distribution
Career attitudes
Emphasis on safety
33. Company Net Sales
(2013)Million USD
Employees
Cipla 1.39 20,000
Dr Reddy’s
Laboratories
1.14 16,300
Ranbaxy Labs 1.07 14,600
Aurobindo Pharma 0.92 8,635
Lupin Ltd 0.91 11,355
Sun Pharma 0.68 11,200
Novartis India 0.14 4,500 (115,000
Worldwide)
Key Players Locally
34. Technological Factors
Technological factors can lower barriers to entry,
reduce minimum efficient production levels, and
influence outsourcing decisions. Some
technological factors include:
R&D activity
Automation
Technology incentives
Rate of technological change
35. GROWTH DRIVERS
Increase in Domestic demands
Rise in outsourcing activities
Growth in Financing products (Health
Insurance)
Increase in disposable income of the
customers
Complications in diseases
41. 1983 • Company set in Vapi, Gujarat
1988
• First few cardiology products launched
1989
• Gastrology products introduced, exports to neighboring
countries began
1994
• IPO in October, listed in major stock exchanges in India,
offering oversubscribed 55 times
1996
• 1st acquisition - an API manufacturing unit from knoll
pharma
Events & timeline of sun pharma
42. 1997
• International acquisition- Caraco pharma Labs, Mj
pharma
2004
• Acquired phlox pharma- Cephalosporin actives
manufacturer
2010
• Acquired Taro pharma, size of US business doubled
2014
• Acquired Ranbaxy labs for $3.2 m, sun becomes largest
company in India, 5th largest globally
Cont.
43. Events & timeline of Cipla
1935
• Company set in Mumbai as a Pharmaceutical
Laboratories
1984
• The name of the company was changed to Cipla ltd.
1985
• US FDA approved the company's bulk drug
manufacturing facilities
1994
• Cipla launched Deferiprone, the world's first oral iron
chelator.
2001
• Cipla offered medicines for HIV treatment at a fractional
cost ( less then $350 per year per patient)
2012
• The company slashed prices of three life-saving cancer
drugs by 50 to64%
44. Events & timeline of Mankind
1995
• Inception of mankind pharma
2000
• Company established its operation all over India
• Launched new division discovery for the segment-
diabetic, metabolic disorder, antibiotics, gastro intestinal,
anti-fungal.
2005
• Launched le fester pharma segment- antibacterial.
• Won the Indian express pharma pulse award for "overall
best performance".
2006
• Established inject able state of the art unit at paonta
sahib
45. Cont.
2007
• Launched future mankind, special mankind, vet
mankind
• Chrys capital became an investor partner
2007
cont.
• Teamed up with Roche diagnostic for the marketing of
product ‘Accuchek go'
2008
• Certified as the most potential& "A" grade vendor in
supply chain management by HINDALCO
2010
• Launched OTC products like prega news, unwanted-72,
don't worry
• Spread the wings globally with the launched of mankind
in Srilanka
46. Cont.
2010
• Established state of art manufacturing unit for liquid
dosages & tablets
2011
• Incorporation of the R&D centre- mankind research
centre in NCR
• Successfully acquired longifene- the former brand of
UCB Belgium
2011
cont.
• Launched a new division "pet Mankind" for the basic
care, health care, hygiene and nutritional need of pet's
2012
• They plan to add another 1000 people to their
workplace within two years .
47. Events & timeline of Z. Cadila healthcare
1952
• Cadila laboratories was founded
2000
• Issue IPO in BSE
2001
• Company required another Indian Pharmaceutical
company called German Remedies
48. Cont.
2007
• Comapny signed an agreement to acquire 100 %
stake in Brazil's Quimica e Farmaceutica Nikkho do
Brasil Ltda ( Nikkho) for around 26 million dollars.
2010
• Received a prestigious Welcome trust award under
the new R&D for affordable healthcare in India
2014
• Launched the world's first adalimumab biosimilar
under the brand name Exemptia (immune disorders)
49. Events & timeline of GSK
1924
• It was established in India under the name of H.J. Foster &
Co. ltd.
2000
• Glaxo wellcome and smithkline beecham announced
their intention to merge and become glaxosmithkline
2002
• The company global headquarters are at GSK house
Brenftord, london officially opened by prime minister
Tony Blair
2005
• Chris Gent , former CEO of Vodaphone, has been the
chair since 2005
2008
• Andrew Witty took over as CEO
50. Cont.
2012
• GSK pleaded guilty to criminal charges in the united
state and agreed to pay a $3 billion settlement ( the
charges related to GSK’s promotion of drugs for
unapproved uses) medicine was anti- depressants
2013
• The company announced that it would no longer
pay physicians to promote its drugs
2015
• Philip Hampton, chair of Royal Bank of Scotland, will
replace Gent in September 2015
51. Current News
Sun Pharma (16 September 2015)
Agreement with US Eye Care firm for around 40 million
US $.
Cipla (17 July 2015)
Announced to by Invagen Pharma inc. & Exelan Pharma
inc. about 550 Million USD in US
52. Cont…
Zydus Cadila (24 June 2015)
Received final approval from US food and drug
administrations (USFDA) to sale Pyridostigmine
Bormide(PGB) Tablets.
GlaxoSmithKline (8 June 2015)
CCI has imposed fine of Rs. 64 Crores for being indulge in
anti competitive activity. It had tried to fix entire bidding
for supply of maligning vaccines for HAZ Pilgrims.
53. Cont…
Mankind’s DHA Campaign (10 September 2015)
MKD has arose the importance of DHA
among children.
They reached 12000 Pediatricians and 20000
children to eliminate the DHA deficiency
from the Indian society in last 8 months.
54. FUTURE TREND
3rd largest pharmaceuticals market by 2020.
20% of global exports in generics.
USD 45 Billion in revenue by 2020.
USD 26.1 Billion in generics by 2016.
USD 200 Billion to be spent on infrastructure by 2024.
49% of all drug master filings registered in the USA.